Novartis blockbuster slate boosts partners' stock
This article was originally published in Scrip
Executive Summary
The UK firm Vernalis saw its share price rise by 10% to 42.36 pence after Novartis included its novel heat shock protein 90 (HSP90) inhibitor AUY922 in a list of seven potential blockbusters in its pipeline, even though the first planned submission is not slated to take place until 2015 or later.